Schultz J E, Hsu A K, Gross G J
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee 53226, USA.
Circulation. 1998 Apr 7;97(13):1282-9. doi: 10.1161/01.cir.97.13.1282.
Our laboratory has previously shown that delta-opioid receptors are involved in the cardioprotective effect of ischemic preconditioning in the rat heart. However, this class of receptors consists of two subtypes, delta1, and delta2, and mu- or kappa-opioid receptors may also exist in the heart. Therefore, the purpose of the present study was to test the hypothesis that ischemic preconditioning is mediated through stimulation of one or both delta-opioid receptor subtypes.
Anesthetized, open chest, male Wistar rats were assigned to 1 of 14 groups. All animals were subjected to 30 minutes of occlusion and 2 hours of reperfusion. Ischemic preconditioning was elicited by three 5-minute occlusion periods interspersed with 5 minutes of reperfusion. Two doses of 7-benzylidenenaltrexone (BNTX; 1 and 3 mg/kg i.v.), a selective delta1-opioid receptor antagonist, or naltriben (NTB; 1 and 3 mg/kg i.v.), a selective delta2-opioid receptor antagonist, were given before ischemic preconditioning. To test for a role of mu-opioid receptors, rats were pretreated with beta-funaltrexamine (beta-FNA; 15 mg/kg s.c), an irreversible mu-opioid receptor antagonist, 24 hours before ischemic preconditioning or given the mu-opioid receptor agonist D-Ala,2N-Me-Phe,4glycerol5-enkephalin (DAMGO) as three 5-minute infusions (1, 10, and 100 microg/kg per infusion i.v., respectively) interspersed with 5-minute drug-free periods before the prolonged ischemic and reperfusion periods (lowDAMGO, medDAMGO, and hiDAMGO, respectively). The involvement of kappa-opioid receptors was tested by administering one of two doses of nor-binaltorphimine (nor-BNI; 1 and 5 mg/kg i.v.) before ischemic preconditioning. Infarct size (IS) as a percent of the area at risk (AAR) was measured by triphenyltetrazolium stain. Ischemic preconditioning markedly reduced IS/AAR (14+/-4%, P<.05) compared with control (55+/-4%). NTB, beta-FNA, and nor-BNI were unable to block the cardioprotective effect of ischemic preconditioning. In addition, DAMGO had no effect on IS/AAR. However, the high dose of BNTX (3 mg/kg i.v.) significantly attenuated the cardioprotective effect of ischemic preconditioning (39+/-5%; P<.05 versus control and ischemic preconditioning).
These results indicate that delta1-opioid receptors play an important role in the cardioprotective effect of ischemic preconditioning in the rat heart.
我们实验室先前已表明,δ-阿片受体参与大鼠心脏缺血预处理的心脏保护作用。然而,这类受体由两种亚型,即δ1和δ2组成,并且μ-或κ-阿片受体也可能存在于心脏中。因此,本研究的目的是检验以下假设:缺血预处理是通过刺激一种或两种δ-阿片受体亚型介导的。
将麻醉的、开胸的雄性Wistar大鼠分为14组中的1组。所有动物均经历30分钟的闭塞和2小时的再灌注。缺血预处理通过三个5分钟的闭塞期并穿插5分钟的再灌注来引发。在缺血预处理前给予两剂7-苄叉基纳曲酮(BNTX;1和3mg/kg静脉注射),一种选择性δ1-阿片受体拮抗剂,或纳曲苄(NTB;1和3mg/kg静脉注射),一种选择性δ2-阿片受体拮抗剂。为了检验μ-阿片受体的作用,在缺血预处理前24小时用β-氟纳曲胺(β-FNA;15mg/kg皮下注射),一种不可逆的μ-阿片受体拮抗剂对大鼠进行预处理,或者在延长的缺血和再灌注期之前给予μ-阿片受体激动剂D-丙氨酸,2N-甲基苯丙氨酸,4-甘油5-脑啡肽(DAMGO),以三次5分钟输注(分别为每次输注1、10和100μg/kg静脉注射)并穿插5分钟无药期(分别为低剂量DAMGO、中剂量DAMGO和高剂量DAMGO)。通过在缺血预处理前给予两剂诺-宾拉托啡(诺-BNI;1和5mg/kg静脉注射)中的一种来检验κ-阿片受体的参与情况。通过三苯基四氮唑染色测量梗死面积(IS)占危险面积(AAR)的百分比。与对照组(55±4%)相比,缺血预处理显著降低了IS/AAR(14±4%,P<0.05)。NTB、β-FNA和诺-BNI均不能阻断缺血预处理的心脏保护作用。此外,DAMGO对IS/AAR无影响。然而,高剂量的BNTX(3mg/kg静脉注射)显著减弱了缺血预处理的心脏保护作用(39±5%;与对照组和缺血预处理组相比,P<0.05)。
这些结果表明,δ1-阿片受体在大鼠心脏缺血预处理的心脏保护作用中起重要作用。